- Home
- PXLW vs ALGS Comparison
PXLW vs ALGS Comparison
Compare PXLW & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PXLW | ALGS |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 34.6M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PXLW | ALGS |
|---|---|---|
| Price | $6.98 | $5.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $14.33 | ★ $39.33 |
| AVG Volume (30 Days) | 39.0K | ★ 63.9K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ 12.07 | N/A |
| Revenue | $693,000.00 | ★ $2,186,000.00 |
| Revenue This Year | $47.19 | $32.20 |
| Revenue Next Year | $30.00 | $4.71 |
| P/E Ratio | $0.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.84 | $3.98 |
| 52 Week High | $15.42 | $13.69 |
Technical Indicators
Market Signals| Indicator | PXLW | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 39.26 |
| Support Level | $5.62 | $4.80 |
| Resistance Level | $7.15 | $6.91 |
| Average True Range (ATR) | 0.25 | 0.57 |
| MACD | -0.02 | -0.20 |
| Stochastic Oscillator | 42.62 | 4.98 |
Price Performance
Historical ComparisonAbout PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.